EBF3

Across TCGA pan-cancer cohorts, EBF3 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated EBF3 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher EBF3 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated EBF3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

UCEC, STAD, and LUSC are the cancer types where EBF3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.933	0.302	.007	18	view →
STAD	OS	Median	All	0.845	0.403	.039	8	view →
LUSC	DFS	Median	All	0.175	0.516	.005	6	view →
ESCA	DFS	Median	II,III,IV	0.173	0.498	.024	6	view →
COAD	DFS	Median	IV	0.028	0.496	<.001	6	view →
LIHC	OS	Median	All	0.061	0.783	<.001	6	view →
ACC	DFS	Median	All	0.140	0.666	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

EBF3–UCEC (DFS)

Open the UCEC breakdown →